Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays.
about
Molecular aspects of severe malariaComparison of sequencing by hybridization and cycle sequencing for genotyping of human immunodeficiency virus type 1 reverse transcriptaseComparisons of substitution, insertion and deletion probes for resequencing and mutational analysis using oligonucleotide microarraysDNA Probe Array for the Simultaneous Identification of Herpesviruses, Enteroviruses, and FlavivirusesInhibition of the HIV-1 and HIV-2 proteases by a monoclonal antibodyCrystallographic analysis of human immunodeficiency virus 1 protease with an analog of the conserved CA-p2 substrate -- interactions with frequently occurring glutamic acid residue at P2' position of substratesAntiviral drug resistance in human cytomegalovirusGenotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir.Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in BrazilEffect of substrate residues on the P2' preference of retroviral proteinasesA mutation in human immunodeficiency virus type 1 protease at position 88, located outside the active site, confers resistance to the hydroxyethylurea inhibitor SC-55389APrevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naïve subjects in the CASTLE studyLow-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral usePrevalence of WHO transmitted drug resistance mutations by deep sequencing in antiretroviral-naïve subjects in Hunan Province, ChinaAn Efficient Microarray-Based Genotyping Platform for the Identification of Drug-Resistance Mutations in Majority and Minority Subpopulations of HIV-1 QuasispeciesDistinguishing HIV-1 drug resistance, accessory, and viral fitness mutations using conditional selection pressure analysis of treated versus untreated patient samples.Chip-based genotyping by mass spectrometryDiscrepant results in the interpretation of HIV-1 drug-resistance genotypic data among widely used algorithms.Recent developments in high-throughput mutation screening.Loading and preparing data for analysis in spotfire.An Escherichia coli expression assay and screen for human immunodeficiency virus protease variants with decreased susceptibility to indinavirMicroarrays for genotyping human group a rotavirus by multiplex capture and type-specific primer extension.Microarray-based identification of antigenic variants of foot-and-mouth disease virus: a bioinformatics quality assessment.Application of broad-spectrum, sequence-based pathogen identification in an urban population.Mutation detection using ENDO1: application to disease diagnostics in humans and TILLING and Eco-TILLING in plants.Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors.Microarrays and toxicology: the advent of toxicogenomics.Principles and applications of methods for DNA-based typing of microbial organisms.Estimate of the frequency of human immunodeficiency virus type 1 protease inhibitor resistance within unselected virus populations in vitro.Science, medicine, and the future. Near patient microbiological tests.Development of molecular genetics.Mutational analysis using oligonucleotide microarrays.Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapyIdentification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.Molecular bacteriology: a diagnostic tool for the millenniumWorldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase.Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapyMonitoring resistance to human immunodeficiency virus type 1 protease inhibitors by pyrosequencing.Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapyVariant human immunodeficiency virus type 1 proteases and response to combination therapy including a protease inhibitor.
P2860
Q24550715-6BFCABA6-FECF-43B3-A848-8BB4C5ED13C9Q24550959-3F67FDAE-6911-4985-8B6D-F65192E4EF9AQ24792059-ADE8F2DF-2812-46A6-ADF8-FD20D0ACAC40Q27471971-4BFDBD73-470F-46F3-8670-BBEA5C3CBD5AQ27620967-9A2D601D-1C2F-4B3E-9615-947D63477043Q27747736-49B448C8-0005-4E7E-87BD-96CB9E50CD63Q28203967-10338979-B90D-4028-9DA4-B674736AFB6FQ28369030-48453D58-D53B-470F-B338-D00580817D5DQ28369565-0FB92A8B-BC29-4692-B995-A1F468DB9CCEQ28372993-7AFB256E-29AB-444A-BEDA-5AE57AE696E9Q28379487-FBA61A58-F677-456E-8898-A0B410E3EC14Q28474221-2BBDC2F9-B2AA-4B21-868F-CA89D53C2BEAQ28475651-EBD1983A-085D-4875-B43B-212A22794DCCQ28539368-E62479C7-34F1-4AAD-A0B4-F4F748232B3DQ28554999-A3778FCA-0BEC-49EF-8A1B-191407431ACDQ30483107-E6012E3F-8244-4C01-9910-F886A076A0BBQ30761976-318E6C56-DD77-44B4-90F3-8FEED6FA765BQ30762478-A419075C-B949-444C-A563-FFAEDC32F212Q30768995-D0FF8BA5-D554-4714-9D01-D007C81E1AE8Q31153294-1C521C15-EFA3-43E5-8863-523CB95DBA24Q31963272-6C8DE4F1-A86E-4197-BDAB-52C93095DAF8Q33194720-FF52E36D-DF2A-4462-89C0-A0B97EE2BC54Q33243910-C0FB93FF-15A2-495A-BBA7-C1EC61A4E64AQ33284609-B73CA0D1-40CD-46D5-8944-22908D9180B3Q33330469-381DD486-6E32-4BF0-92B2-13CDF0E58020Q33593237-D7D86D34-1410-4EBD-BBEB-6583D3BDEBFCQ33594789-FCA74FDD-7288-4633-A461-E63F6601B29CQ33633845-9D0C4F05-2457-40F1-981E-2970C343340FQ33690287-7C08001C-A60A-4EA1-94B6-F5D00AA45D0CQ33699691-57E9A616-4688-4BBC-97C4-C5538171F354Q33746321-02322BF6-CB82-4627-87DF-22427E61CEBAQ33755554-B06761AE-0D15-46D9-969F-E77A33AFE1CAQ33782492-98AFC32B-5126-4512-BCB2-22F8D864EDC1Q33804495-2840973C-AF1B-423C-B013-82E1931CCE5AQ33893067-FFBABF29-F124-4384-916E-A548C1B7DD30Q33961507-FC72B04C-0A5A-4084-A18A-4B8E6E3A47BDQ33971104-2409189F-FA35-4695-B030-116A3ECF639AQ33971117-BA8D82FA-F9B5-4F0B-8FD1-1DD90BDF8A7DQ33980528-2F0FEB11-BC22-4632-B17B-A087316F3667Q33981706-43957754-F984-467F-9A8F-86E4A86B5BE4
P2860
Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
Extensive polymorphisms observ ...... ensity oligonucleotide arrays.
@en
Extensive polymorphisms observ ...... ensity oligonucleotide arrays.
@nl
type
label
Extensive polymorphisms observ ...... ensity oligonucleotide arrays.
@en
Extensive polymorphisms observ ...... ensity oligonucleotide arrays.
@nl
prefLabel
Extensive polymorphisms observ ...... ensity oligonucleotide arrays.
@en
Extensive polymorphisms observ ...... ensity oligonucleotide arrays.
@nl
P2093
P2860
P356
P1433
P1476
Extensive polymorphisms observ ...... density oligonucleotide arrays
@en
P2093
D D Richman
T C Merigan
P2860
P2888
P304
P356
10.1038/NM0796-753
P407
P577
1996-07-01T00:00:00Z